ML achieves Federal Circuit victory for client Merck

In a victory for our client Merck, the Federal Circuit affirmed the PTAB’s judgment rejecting a competitor’s challenges, on grounds of anticipation and obviousness, to a Merck patent relating to the treatment of Type-2 diabetes.  Read our client’s response brief and the opinion.